497 related articles for article (PubMed ID: 19797507)
1. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
Chung SJ; Kim JK; Park MC; Park YB; Lee SK
J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-tumor necrosis factor-α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan.
Cho YT; Chen CH; Chiu HY; Tsai TF
J Dermatol; 2012 Mar; 39(3):269-73. PubMed ID: 22077677
[TBL] [Abstract][Full Text] [Related]
4. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus.
Zhang X; Zhang F; Wu D; Bao C; Zhu P; Zhang X; Huang C; He D; Tao Y; Fang Y; Gu J; Wu H; Sun L; Yang X; Huang F; Xu H; Zhao D; Zhang M; Zheng Y; Li Z
Int J Rheum Dis; 2013 Aug; 16(4):408-12. PubMed ID: 23992260
[TBL] [Abstract][Full Text] [Related]
5. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
6. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
[TBL] [Abstract][Full Text] [Related]
7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.
Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI
Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596
[TBL] [Abstract][Full Text] [Related]
9. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.
Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM
Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
[TBL] [Abstract][Full Text] [Related]
11. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.
Caporali R; Bobbio-Pallavicini F; Atzeni F; Sakellariou G; Caprioli M; Montecucco C; Sarzi-Puttini P
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):749-54. PubMed ID: 20535784
[TBL] [Abstract][Full Text] [Related]
12. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
14. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase.
Chu CM; Chen YC; Tai DI; Liaw YF
Clin Gastroenterol Hepatol; 2010 Jun; 8(6):535-40. PubMed ID: 20304099
[TBL] [Abstract][Full Text] [Related]
15. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
17. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
20. [Follow-up of chronic hepatitis B carriers. Serological course and risk of reactivation].
Bujanda L; García Bengoechea M; Cilla G; Gil I; yArenas JI
Rev Esp Enferm Dig; 1996 May; 88(5):335-9. PubMed ID: 8764540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
